JP2016540503A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540503A5
JP2016540503A5 JP2016532031A JP2016532031A JP2016540503A5 JP 2016540503 A5 JP2016540503 A5 JP 2016540503A5 JP 2016532031 A JP2016532031 A JP 2016532031A JP 2016532031 A JP2016532031 A JP 2016532031A JP 2016540503 A5 JP2016540503 A5 JP 2016540503A5
Authority
JP
Japan
Prior art keywords
antibody polypeptide
antibody
seq
emitters
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540503A (ja
JP6599859B2 (ja
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/053420 external-priority patent/WO2015075445A1/en
Publication of JP2016540503A publication Critical patent/JP2016540503A/ja
Publication of JP2016540503A5 publication Critical patent/JP2016540503A5/ja
Application granted granted Critical
Publication of JP6599859B2 publication Critical patent/JP6599859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532031A 2013-11-19 2014-11-19 ヒト化抗カリクレイン−２抗体 Active JP6599859B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB1320408.6 2013-11-19
GB1401973.1 2014-02-05
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof
PCT/GB2014/053420 WO2015075445A1 (en) 2013-11-19 2014-11-19 Humanised anti kallikrein-2 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019181801A Division JP7051777B2 (ja) 2013-11-19 2019-10-02 ヒト化抗カリクレイン－２抗体

Publications (3)

Publication Number Publication Date
JP2016540503A JP2016540503A (ja) 2016-12-28
JP2016540503A5 true JP2016540503A5 (https=) 2017-12-28
JP6599859B2 JP6599859B2 (ja) 2019-10-30

Family

ID=52114029

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016532031A Active JP6599859B2 (ja) 2013-11-19 2014-11-19 ヒト化抗カリクレイン−２抗体
JP2019181801A Active JP7051777B2 (ja) 2013-11-19 2019-10-02 ヒト化抗カリクレイン－２抗体
JP2022003634A Active JP7592654B2 (ja) 2013-11-19 2022-01-13 ヒト化抗カリクレイン－２抗体
JP2024201463A Pending JP2025019101A (ja) 2013-11-19 2024-11-19 ヒト化抗カリクレイン－２抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019181801A Active JP7051777B2 (ja) 2013-11-19 2019-10-02 ヒト化抗カリクレイン－２抗体
JP2022003634A Active JP7592654B2 (ja) 2013-11-19 2022-01-13 ヒト化抗カリクレイン－２抗体
JP2024201463A Pending JP2025019101A (ja) 2013-11-19 2024-11-19 ヒト化抗カリクレイン－２抗体

Country Status (24)

Country Link
US (3) US10100125B2 (https=)
EP (2) EP3553088B1 (https=)
JP (4) JP6599859B2 (https=)
KR (3) KR102442738B1 (https=)
CN (2) CN112898431B (https=)
AU (3) AU2014351611B2 (https=)
BR (1) BR112016011025B1 (https=)
CA (1) CA2930493A1 (https=)
CY (1) CY1121900T1 (https=)
DK (2) DK3071595T3 (https=)
ES (1) ES2728515T3 (https=)
FI (1) FI3553088T3 (https=)
HR (1) HRP20191095T1 (https=)
HU (1) HUE043875T2 (https=)
IL (5) IL297678B2 (https=)
LT (1) LT3071595T (https=)
MX (2) MX383543B (https=)
PL (1) PL3071595T3 (https=)
PT (1) PT3071595T (https=)
RS (1) RS58831B1 (https=)
RU (1) RU2687163C1 (https=)
SI (1) SI3071595T1 (https=)
SM (1) SMT201900338T1 (https=)
WO (1) WO2015075445A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013061083A2 (en) 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
WO2017087826A1 (en) * 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
AU2020322221A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)
BR112022001368A2 (pt) 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
EP4182353A1 (en) 2020-07-17 2023-05-24 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
UY39510A (es) * 2020-11-10 2022-05-31 Janssen Biotech Inc Compuestos macrocíclicos y métodos para usarlos
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
JP2024503924A (ja) * 2021-01-27 2024-01-29 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含む免疫コンジュゲート及びその使用
WO2022165130A1 (en) * 2021-01-28 2022-08-04 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof
US20230011134A1 (en) * 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
CA3240194A1 (en) 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
JP2024543046A (ja) 2021-11-09 2024-11-19 ヤンセン バイオテツク，インコーポレーテツド 大環状化合物及びその診断上の使用
EP4469095A1 (en) 2022-01-26 2024-12-04 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CN1238013A (zh) 1996-11-14 1999-12-08 梅奥医学教育及研究基金会 转移性前列腺癌的检测方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
WO2001012218A1 (en) 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20040219163A1 (en) * 2001-10-03 2004-11-04 Frelinger John G. Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
EP2347767A3 (en) 2003-01-31 2013-06-12 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
ES2560868T3 (es) * 2006-12-22 2016-02-23 Phadia Ab Alérgeno de calicreína de próstata novedoso
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2013061083A2 (en) * 2011-10-28 2013-05-02 Fredax Ab Therapeutic agents and uses thereof
SMT201900338T1 (it) 2013-11-19 2019-07-11 Fredax Ab Anticopri anti-callicreina-2 umanizzato
WO2023278463A1 (en) 2021-06-29 2023-01-05 Volastra Therapeutics, Inc. Anti-enpp1 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2016540503A5 (https=)
JP7051777B2 (ja) ヒト化抗カリクレイン－２抗体
Orlova et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
Kenanova et al. Tailoring antibodies for radionuclide delivery
Kraeber-Bodéré et al. Radioimmunoconjugates for the treatment of cancer
Navarro-Teulon et al. General overview of radioimmunotherapy of solid tumors
Olafsen et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
JP2017532952A5 (https=)
JP2019511222A5 (https=)
HRP20170879T1 (hr) Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena
JP2011501656A5 (https=)
JP2014530898A5 (https=)
JP2018531045A5 (https=)
RU2018115734A (ru) Полипептиды антител и их применение
GB2520353A (en) Antibody polypeptides and uses thereof
Hauck et al. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia
EP2193147B1 (en) Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and use thereof
BR112018002451B1 (pt) Região de dobramento de aminoácidos e composição farmacêutica
JPWO2010131590A1 (ja) 腫瘍の診断剤又は治療剤